Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Carlos King-Ho WongKenneth Keng Cheung ManMargaret ShiEsther Wai Yin ChanChu Wa HoEmily Tsui Yee TseIan Chi Kei Ck WongCindy L K LamPublished in: PLoS medicine (2019)
Our results indicated that, for patients with T2DM who are on Met-SU dual therapy, the addition of DPP4i was a preferred third-line medication among 3 options, with the lowest risks of mortality and SH and posing no increased risk for CVD events when compared to insulin and TZD. Intensification with insulin had the greatest risk of mortality and SH events.
Keyphrases
- type diabetes
- glycemic control
- end stage renal disease
- cardiovascular disease
- cardiovascular events
- ejection fraction
- newly diagnosed
- human health
- chronic kidney disease
- healthcare
- risk factors
- prognostic factors
- peritoneal dialysis
- insulin resistance
- early onset
- mesenchymal stem cells
- patient reported outcomes
- bone marrow
- tyrosine kinase
- risk assessment
- climate change
- skeletal muscle
- patient reported
- replacement therapy